At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 enrolled
Drug / intervention
SNS-595drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Intravenous Administration of SNS-595 in Patients With Advanced Small Cell Lung Cancer (SCLC)
In Brief
A Phase 2 clinical trial evaluating SNS-595 for Carcinoma, Small Cell and Small Cell Lung Cancer. Completed, enrolled 55 participants across 17 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the objective tumor response rate to SNS-595 in patients with small cell lung cancer (SCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Small Cell, Small Cell Lung Cancer
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
First PostedMar 2006
Primary CompletionAug 2007
Study CompletionJun 2008
TodayJul 2026
First PostedMar 3, 2006
Enrollment StartFeb 1, 2006
Primary CompletionAug 1, 2007
Study CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 20.3 years ago
Interventions
SNS-595drug